Zanubrutinib, Obinutuzumab, and Venetoclax With MRD-Driven Discontinuation in Previously Untreated Patients With CLL or Small Lymphocytic Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Lancet Haematol 2021 Dec 01;8(12)e879-e890, JD Soumerai, AR Mato, A Dogan, VE Seshan, E Joffe, K Flaherty, J Carter, E Hochberg, JA Barnes, AM Hamilton, JS Abramson, CL Batlevi, MJ Matasar, A Noy, CN Owens, ML Palomba, A Kumar, T Takvorian, A Ni, M Choma, C Friedman, P Chadha, E Simkins, J Ruiters, S Sechio, D Portman, L Ramos, N Nolet, N Mahajan, R Martignetti, J Mi, K Scorsune, J Lynch, B McGree, S Hughes, C Grieve, LE Roeker, M Thompson, PC Johnson, M Roshal, J Huang, J Biondo, Q Wu, A Jacob, O Abdel-Wahab, AD ZelenetzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.